Pfizer Ventures led the Series B financing of Cartography Biosciences, whose lead program addresses a promising target for colorectal cancer. The startup’s drugs come from platform technologies that analyze data from healthy cells and cancer cells to identify cancer-specific targets.
The post Cartography Bio Corrals $67M to Bring Targeted Colorectal Cancer Drug Into the Clinic appeared first on MedCity News.
